Reporting owner · CIK 0001727334

Robinson Chandler

SEC Form 4 history for the last 180 days across 1 company, 12 transactions and 3 filings.

CEOChief Executive OfficerMonopar Therapeutics
Open-market transaction mix0% buys0 buys · 4 sales

Period: Last 180 days

Trade dates in this period: Sep 24, 2026 – Oct 20, 2026

Transaction history, summary figures and purchase returns cover the last 180 days. Earlier activity is excluded from those sections.

Filings3Form 4 records
Buying$00 purchases
Selling$2.56M4 sales
Net value−$2.56MBuys minus sells · disclosed values

Latest insider transactions

Form 4 filings from the last 180 days.
Robinson Chandler transactions · 20 per page
CompanyActivityDisclosed valueFiled (ET)
MNPRMonopar Therapeutics
CEO
CEO. Role codes can represent multiple titles; the list does not include the filing title.
Tax withholding
Form 4 code F. Payment of an exercise price or tax liability by delivering or withholding securities in a Rule 16b-3 transaction.
SEC filing ↗
−$55.3kView disclosure →
MNPRMonopar Therapeutics
CEO
CEO. Role codes can represent multiple titles; the list does not include the filing title.
Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
Derivative securitySEC filing ↗
$0View disclosure →
MNPRMonopar Therapeutics
CEO
CEO. Role codes can represent multiple titles; the list does not include the filing title.
Tax withholding
Form 4 code F. Payment of an exercise price or tax liability by delivering or withholding securities in a Rule 16b-3 transaction.
SEC filing ↗
−$346kView disclosure →
MNPRMonopar Therapeutics
CEO
CEO. Role codes can represent multiple titles; the list does not include the filing title.
Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
SEC filing ↗
—View disclosure →
MNPRMonopar Therapeutics
CEO
CEO. Role codes can represent multiple titles; the list does not include the filing title.
Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
Pre-planned (10b5-1)
10b5-1 plan language detected in footnotes; absence does not prove a discretionary trade.
Derivative securitySEC filing ↗
$0View disclosure →
MNPRMonopar Therapeutics
CEO
CEO. Role codes can represent multiple titles; the list does not include the filing title.
Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
Pre-planned (10b5-1)
10b5-1 plan language detected in footnotes; absence does not prove a discretionary trade.
Derivative securitySEC filing ↗
$0View disclosure →
MNPRMonopar Therapeutics
CEO
CEO. Role codes can represent multiple titles; the list does not include the filing title.
Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
Pre-planned (10b5-1)
10b5-1 plan language detected in footnotes; absence does not prove a discretionary trade.
SEC filing ↗
−$53.9kView disclosure →
MNPRMonopar Therapeutics
CEO
CEO. Role codes can represent multiple titles; the list does not include the filing title.
Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
Pre-planned (10b5-1)
10b5-1 plan language detected in footnotes; absence does not prove a discretionary trade.
SEC filing ↗
−$745kView disclosure →
MNPRMonopar Therapeutics
CEO
CEO. Role codes can represent multiple titles; the list does not include the filing title.
Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
Pre-planned (10b5-1)
10b5-1 plan language detected in footnotes; absence does not prove a discretionary trade.
SEC filing ↗
−$848kView disclosure →
MNPRMonopar Therapeutics
CEO
CEO. Role codes can represent multiple titles; the list does not include the filing title.
Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
Pre-planned (10b5-1)
10b5-1 plan language detected in footnotes; absence does not prove a discretionary trade.
SEC filing ↗
−$911kView disclosure →
MNPRMonopar Therapeutics
CEO
CEO. Role codes can represent multiple titles; the list does not include the filing title.
Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
Pre-planned (10b5-1)
10b5-1 plan language detected in footnotes; absence does not prove a discretionary trade.
SEC filing ↗
$210kView disclosure →
MNPRMonopar Therapeutics
CEO
CEO. Role codes can represent multiple titles; the list does not include the filing title.
Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
Pre-planned (10b5-1)
10b5-1 plan language detected in footnotes; absence does not prove a discretionary trade.
SEC filing ↗
$422kView disclosure →

Latest Form 4 facts

Quick context from source filings

Latest open-market transaction

The insider reported a sale at Monopar Therapeutics on Sep 24, 2026 valued at $53,874.

Review SEC filing
Latest buy

No open-market insider purchase is available.

Monthly open-market activity

Last 2 reported months · purchases and sales

View exact monthly values
Monthly open-market source values
MonthPurchasesSalesBuy valueSale valueNet value
Sep 202604$0$2,556,850.94−$2,556,850.94
Oct 202600$0$0$0

Net value is disclosed purchases minus sales, not profit. A dash means the value is unavailable.

Ownership and transaction size

Ownership and ticket size

Average P/S size$639k
Median P/S size$796k
Direct12
Indirect0
Oct 20, 2026withholding

Associated companies

Counts cover all available history, including outside the summary period

Open-market buy performance

90-day forward return on this insider's open-market purchases

90d forward
No open-market purchases in the last 180 days

A 90-day purchase return requires an open-market buy. None is recorded in the last 180 days. Purchases filed earlier are outside the visible history and are not included.

Disclosed ownership

How reported shareholdings evolved

Non-derivative shares held after reported transactions—not stock prices or a complete portfolio.

9 observations · Sep 24, 2026 – Oct 20, 2026. Window ends at the latest available report, not today.

Selected observation · Oct 20, 2026104,127 shares reported
Inspect transaction
View exact observations and source transactions
Transaction dateShares held afterFiledSource
Sep 24, 2026113,323Sep 28, 2026View transaction
Sep 24, 2026128,323Sep 28, 2026View transaction
Sep 24, 2026117,873Sep 28, 2026View transaction
Sep 24, 2026108,235Sep 28, 2026View transaction
Sep 24, 202699,867Sep 28, 2026View transaction
Sep 24, 202699,267Sep 28, 2026View transaction
Sep 30, 2026109,068Oct 2, 2026View transaction
Sep 30, 2026104,724Oct 2, 2026View transaction
Oct 20, 2026104,127Oct 20, 2026View transaction

Securities and direct/indirect ownership contexts are kept separate and never summed. Joint filings may associate the same disclosed row with multiple owners. Unknown values are omitted, not treated as zero. Lines connect observations for readability; they do not establish holdings between filings, cost basis, or current ownership. Amendments and stock splits require reviewing the source.

Robinson Chandler Insider Activity FAQ

SEC Form 4 context

Who is Robinson Chandler?

Robinson Chandler is a reporting owner in SEC Form 4 filings with reporting owner CIK 0001727334.

Which companies has Robinson Chandler reported transactions for?

Monopar Therapeutics

When was Robinson Chandler's latest insider buy?

No open-market insider purchase is recorded in the last 180 days. Earlier filings are outside the visible history.

When was Robinson Chandler's latest insider sale?

The insider reported a sale at Monopar Therapeutics on Sep 24, 2026 valued at $53,874.

Where can I see the original SEC filings?

Each transaction row links directly to the source SEC filing so the reported Form 4 details can be reviewed.

Are performance metrics included?

The profile shows average and median 90-day stock returns after open-market purchases when price coverage is available. These are unadjusted stock returns, not realized trading gains. Win rates, benchmark-adjusted returns and conviction scores are not calculated.